Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.
Amyloid beta-peptide (Abeta) is a major constituent of senile plaques in Alzheimer's disease (AD). Neurotoxicity results from the conformational transition of Abeta from random-coil to beta-sheet and its oligomerization. Among a series of ionic compounds able to interact with soluble Abeta, Tramiprosate (3-amino-1-propanesulfonic acid; 3APS; Alzhemedtrade mark) was found to maintain Abeta in a non-fibrillar form, to decrease Abeta(42)-induced cell death in neuronal cell cultures, and to inhibit amyloid deposition. Tramiprosate crosses the murine blood-brain barrier (BBB) to exert its activity. Treatment of TgCRND8 mice with Tramiprosate resulted in significant reduction (approximately 30%) in the brain amyloid plaque load and a significant decrease in the cerebral levels of soluble and insoluble Abeta(40) and Abeta(42) (approximately 20-30%). A dose-dependent reduction (up to 60%) of plasma Abeta levels was also observed, suggesting that Tramiprosate influences the central pool of Abeta, changing either its efflux or its metabolism in the brain. We propose that Tramiprosate, which targets soluble Abeta, represents a new and promising therapeutic class of drugs for the treatment of AD.
Gervais
Francine
F
Neurochem Inc., 275 Armand-Frappier Blvd., Laval, QC, Canada H7V 4A7.
Paquette
Julie
J
Morissette
Céline
C
Krzywkowski
Pascale
P
Yu
Mathilde
M
Azzi
Mounia
M
Lacombe
Diane
D
Kong
Xianqi
X
Aman
Ahmed
A
Laurin
Julie
J
Szarek
Walter A
WA
Tremblay
Patrick
P